J'Nisha Jolani Aquino Manibusan, PA
Physician Assistant · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 1 carrier
- Offices
- 3
Offices
3 locations · One Medical Group Inc · 330 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call J'Nisha Jolani Aquino Manibusan’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Drugs they prescribed that Part D paid
$172,243
Pharmacies billed $172,243 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
569 generic and fewer than 11 brand-name prescriptions · $172,243 in drug cost · 16 antibiotic prescriptions to 12 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Jardiance | 40 | $34,695 | $867 |
| Rybelsus | 11 | $13,718 | $1,247 |
| Farxiga | 11 | $8,007 | $728 |
| Trintellix | 12 | $5,662 | $472 |
| Atorvastatin | 79 | $440 | $6 |
See all 22 drugs
| Jardiance | 40 | $34,695 | $867 |
| Rybelsus | 11 | $13,718 | $1,247 |
| Farxiga | 11 | $8,007 | $728 |
| Trintellix | 12 | $5,662 | $472 |
| Atorvastatin | 79 | $440 | $6 |
| Tamsulosin | 15 | $417 | $28 |
| Albuterol Sulfate Hfa | 12 | $338 | $28 |
| Losartan | 49 | $309 | $6 |
| Metformin | 46 | $300 | $7 |
| Amlodipine Besylate | 34 | $216 | $6 |
| Rosuvastatin | 12 | $186 | $15 |
| Lisinopril | 26 | $154 | $6 |
| Pantoprazole | 20 | $144 | $7 |
| Metoprolol | 14 | $137 | $10 |
| Alendronate | 20 | $124 | $6 |
| Gabapentin | 12 | $120 | $10 |
| Levothyroxine | 19 | $116 | $6 |
| Fluticasone Propionate | 13 | $94 | $7 |
| Escitalopram | 11 | $62 | $6 |
| Omeprazole | 16 | $59 | $4 |
| Sumatriptan | 14 | $44 | $3 |
| Hydrochlorothiazide | 11 | $10 | $1 |
Year by year
| 2024 | 709 | 67 | None | None | $172,243 |
| 2023 | 457 | 69 | None | None | $118,185 |
| 2022 | 197 | 40 | None | None | $20,659 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 12 drugs
| Myrbetriq | 12 | $5,795 | $483 |
| Symbicort | 11 | $4,641 | $422 |
| Diclofenac | 25 | $803 | $32 |
| Ventolin Hfa | 11 | $680 | $62 |
| Atorvastatin | 36 | $679 | $19 |
| Metformin | 15 | $481 | $32 |
| Losartan | 36 | $427 | $12 |
| Oxybutynin Chloride Er | 12 | $257 | $21 |
| Alendronate | 15 | $230 | $15 |
| Amlodipine Besylate | 15 | $222 | $15 |
| Levothyroxine | 17 | $203 | $12 |
| Trazodone | 11 | $86 | $8 |
2022: 2 drugs
| Atorvastatin | 13 | $395 | $30 |
| Losartan | 11 | $33 | $3 |
Money from drug and device companies
$122 in 2025
| 2025 | 1 | 1 | None | $122 |
| 2024 | 13 | 31 | None | $688 |
| 2023 | 9 | 17 | None | $407 |
| 2022 | 12 | 28 | None | $965 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Gilead Sciences | Yeztugo | $122 | 1 payment
|
See the published payment
| Gilead Sciences | Meals · 2025-08-14 | Yeztugo | $122 |
See earlier years (2024, 2023, 2022)
2024: $688
| Abbvie | Vraylar | $136 | 13 payments
|
| Otsuka America Pharmaceutical | Rexulti | $109 | 1 payment
|
| ViiV Healthcare | Apretude | $103 | 1 payment
|
| Novo Nordisk | Wegovy | $85 | 4 payments
|
| Pfizer | Prevnar 20 | $38 | 2 payments
|
| Lilly USA | Mounjaro | $38 | 2 payments
|
| Merck Sharp & Dohme | Gardasil | $38 | 2 payments
|
| Indivior | Perseris | $29 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Synjardy | $26 | 1 payment
|
| Exact Sciences | Cologuard Collection Kit | $25 | 1 payment
|
| GlaxoSmithKline | Bexsero | $21 | 1 payment
|
| Dexcom | Dexcom G6 Transmitter | $21 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $19 | 1 payment
|
2023: $407
| Abbvie | Vraylar | $169 | 6 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $53 | 2 payments
|
| Pfizer | Prevnar 20 | $48 | 2 payments
|
| Exact Sciences | Cologuard Collection Kit | $45 | 2 payments
|
| Teva Pharmaceuticals USA | Uzedy | $26 | 1 payment
|
| Novo Nordisk | Rybelsus | $24 | 1 payment
|
| Merck Sharp & Dohme | Rotateq | $18 | 1 payment
|
| Lilly USA | Mounjaro | $17 | 1 payment
|
| Organon | Nexplanon | $8 | 1 payment
|
2022: $965
| Lilly USA | Mounjaro | $229 | 7 payments
|
| Novo Nordisk | Ozempic | $196 | 6 payments
|
| ViiV Healthcare | Apretude | $113 | 1 payment
|
| Organon | Nexplanon | $97 | 5 payments
|
| GlaxoSmithKline | Shingrix | $95 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $85 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $46 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $26 | 1 payment
|
| Pfizer | Prevnar 20 | $24 | 1 payment
|
| Gilead Sciences | None | $20 | 1 payment
|
| Sanofi Pasteur | Vaxelis | $17 | 1 payment
|
| Sanofi-Aventis U.S. | Toujeo | $17 | 1 payment
|
Professional record
- NPI
- 1043985856
- Licence
- CA PA60280
- Trained
- Loma Linda University School of Medicine, 2021
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Physician assistant (363A00000X)
- Mailing address
- 1 Embarcadero Ctr Ste 1900, San Francisco, CA, 94111
- NPI first listed
- 2021-08-12
- NPI last updated
- 2024-09-25
- NPI record certified
- 2024-09-25
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 785 Camino Del Sur Apt 301, Goleta, CA, 93117